中国循证心血管医学杂志
中國循證心血管醫學雜誌
중국순증심혈관의학잡지
CHINESE JOURNAL OF EVIDENCE-BASES CARDIOVASCULAR MEDICINE
2014年
1期
25-30
,共6页
李银花%贾张蓉%江龙%杨秋%王绿娅
李銀花%賈張蓉%江龍%楊鞦%王綠婭
리은화%가장용%강룡%양추%왕록아
血脂康%高脂血症%冠心病%Meta分析
血脂康%高脂血癥%冠心病%Meta分析
혈지강%고지혈증%관심병%Meta분석
Xuezhikang%Hyperlipemia%Coronary heart disease%Meta-analysis
目的:评价血脂康治疗冠心病合并高脂血症患者的疗效。方法计算机检索PubMed、Cochrane图书馆、EBSCO host、中国学术期刊网络出版总库(CNKI)、万方医学数据库、维普中文科技期刊全文数据库(VIP),检查时间为2013年10月之前。纳入标准为血脂康治疗高脂血症的随机对照试验。采用Revman 5.2软件进行Meta分析。系统评价血脂康对血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)的影响。结果共纳入19项随机对照试验,包括6229例患者。Meta分析显示,在冠心病常规治疗的基础上,血脂康组较安慰剂组TC、TG、LDL-C显著降低[(WMD=-1.15,95%CI:-1.67~-0.64,P<0.001)、(WMD=-0.51,95%CI:-0.83~-0.20,P=0.002)、(WMD=-0.99,95%CI:-1.38~-0.59,P<0.001)],HDL-C明显升高(WMD=0.21,95%CI:0.05~0.38,P=0.01);血脂康组较单纯常规治疗组TC、TG、LDL-C显著降低[(WMD=-1.19,95%CI:-1.45~-0.93,P<0.001)、(WMD=-1.19,95%CI:-1.45~-0.93, P<0.001)、(WMD=-1.00,95%CI:-1.27~-0.73,P<0.001)],HDL-C显著升高(WMD=0.17,95%CI:0.05~0.29,P=0.007)];血脂康与他汀类药物相比TC、TG、LDL-C、HDL-C差异均无统计学意义。结论在冠心病常规治疗的基础上,可有效调节血脂,与他汀类药物作用相当。
目的:評價血脂康治療冠心病閤併高脂血癥患者的療效。方法計算機檢索PubMed、Cochrane圖書館、EBSCO host、中國學術期刊網絡齣版總庫(CNKI)、萬方醫學數據庫、維普中文科技期刊全文數據庫(VIP),檢查時間為2013年10月之前。納入標準為血脂康治療高脂血癥的隨機對照試驗。採用Revman 5.2軟件進行Meta分析。繫統評價血脂康對血清總膽固醇(TC)、甘油三酯(TG)、低密度脂蛋白膽固醇(LDL-C)、高密度脂蛋白膽固醇(HDL-C)的影響。結果共納入19項隨機對照試驗,包括6229例患者。Meta分析顯示,在冠心病常規治療的基礎上,血脂康組較安慰劑組TC、TG、LDL-C顯著降低[(WMD=-1.15,95%CI:-1.67~-0.64,P<0.001)、(WMD=-0.51,95%CI:-0.83~-0.20,P=0.002)、(WMD=-0.99,95%CI:-1.38~-0.59,P<0.001)],HDL-C明顯升高(WMD=0.21,95%CI:0.05~0.38,P=0.01);血脂康組較單純常規治療組TC、TG、LDL-C顯著降低[(WMD=-1.19,95%CI:-1.45~-0.93,P<0.001)、(WMD=-1.19,95%CI:-1.45~-0.93, P<0.001)、(WMD=-1.00,95%CI:-1.27~-0.73,P<0.001)],HDL-C顯著升高(WMD=0.17,95%CI:0.05~0.29,P=0.007)];血脂康與他汀類藥物相比TC、TG、LDL-C、HDL-C差異均無統計學意義。結論在冠心病常規治療的基礎上,可有效調節血脂,與他汀類藥物作用相噹。
목적:평개혈지강치료관심병합병고지혈증환자적료효。방법계산궤검색PubMed、Cochrane도서관、EBSCO host、중국학술기간망락출판총고(CNKI)、만방의학수거고、유보중문과기기간전문수거고(VIP),검사시간위2013년10월지전。납입표준위혈지강치료고지혈증적수궤대조시험。채용Revman 5.2연건진행Meta분석。계통평개혈지강대혈청총담고순(TC)、감유삼지(TG)、저밀도지단백담고순(LDL-C)、고밀도지단백담고순(HDL-C)적영향。결과공납입19항수궤대조시험,포괄6229례환자。Meta분석현시,재관심병상규치료적기출상,혈지강조교안위제조TC、TG、LDL-C현저강저[(WMD=-1.15,95%CI:-1.67~-0.64,P<0.001)、(WMD=-0.51,95%CI:-0.83~-0.20,P=0.002)、(WMD=-0.99,95%CI:-1.38~-0.59,P<0.001)],HDL-C명현승고(WMD=0.21,95%CI:0.05~0.38,P=0.01);혈지강조교단순상규치료조TC、TG、LDL-C현저강저[(WMD=-1.19,95%CI:-1.45~-0.93,P<0.001)、(WMD=-1.19,95%CI:-1.45~-0.93, P<0.001)、(WMD=-1.00,95%CI:-1.27~-0.73,P<0.001)],HDL-C현저승고(WMD=0.17,95%CI:0.05~0.29,P=0.007)];혈지강여타정류약물상비TC、TG、LDL-C、HDL-C차이균무통계학의의。결론재관심병상규치료적기출상,가유효조절혈지,여타정류약물작용상당。
Objective To review the lipid-regulation effect of Xuezhikang in patients with coronary heart disease (CHD) complicating hyperlipemia. Methods The databases of PubMed, Cochrane Library, EBSCO host, CNKI, WangFang Database and Vip Database were retrieved with computer until to Oct. 2013. The randomized controlled trials (RCT) were collected and read and extracted by two independent researches. The data was given a Meta-analysis by using Revman 5.2 software. The influences of Xuezhikang on the levels of cholesterol (TC), triglyceride (TG), low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein-cholesterol (HDL-C) were reviewed systematically. Results There were totally 19 RCT included involving 6229 cases. The Meta-analysis showed that on the base of CHD routine treatment, the levels of TC, TG and LDL-C decreased significantly [(WMD=-1.15, 95%CI:-1.67~-0.64, P<0.001), (WMD=-0.51, 95%CI:-0.83~-0.20, P=0.002), (WMD=-0.99, 95%CI: -1.38~-0.59, P<0.001)], and HDL-C level increased significantly (WMD=0.21, 95%CI: 0.05~0.38, P=0.01) in Xuezhikang group compared with placebo group. The levels of TC, TG and LDL-C decreased significantly [(WMD=-1.19, 95%CI:-1.45~-0.93, P<0.001), (WMD=-1.19, 95%CI:-1.45~-0.93, P<0.001), (WMD=-1.00, 95%CI:-1.27~-0.73, P<0.001)], and HDL-C level increased significantly (WMD=0.17, 95%CI:0.05~0.29, P=0.007) in Xuezhikang group compared with routine treatment group. The levels of TC, TG, LDL-C and HDL-C had no statistical significance between Xuezhikang and statins. Conclusion On the base of CHD routine treatment, Xuezhikang can regulate blood fat effectively and its effect is similar to that of statins.